Evotec SE (EVO) Capital Expenditures Growth (1y) (2010 - 2026)
Evotec SE (EVO) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 32.98% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -21.54% |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 74.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.54% |
| Dec 31, 2025 | -32.73% |
| Sep 30, 2025 | 19.66% |
| Jun 30, 2025 | 42.04% |
| Mar 31, 2025 | 56.21% |
| Dec 31, 2024 | -45.30% |
| Sep 30, 2024 | 41.18% |
| Jun 30, 2024 | 76.31% |
| Mar 31, 2024 | -194.47% |
| Dec 31, 2023 | 24.24% |
| Sep 30, 2023 | -120.78% |
| Jun 30, 2023 | -290.52% |
| Mar 31, 2023 | 196.05% |
| Dec 31, 2022 | 35.98% |
| Sep 30, 2022 | 638.80% |
| Jun 30, 2022 | -146.92% |
| Mar 31, 2022 | -109,924.74% |
| Jun 30, 2010 | -392.29% |
| Mar 31, 2010 | -391.93% |